U.S. pharmaceutical Eli Lilly is partnering with Chinese drugmaker Shanghai Junshi Biosciences to develop new antibody therapies for COVID-19, the disease that has sickened 3.6 million people worldwide.
Caixin
Eli Lilly partners with Shanghai Junshi for COVID-19 cure
Deal empowers Chinese company to fast-track promising coronavirus therapies